incomplete Freund's adjuvant
Trials 11
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 120 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | incomplete Freund's adjuvant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00089063 ↗ |
| Known as | Montanide | “Montanide ISA-51 (Incomplete Freund's Adjuvant)” PMID 26500235 ↗ Oct 2015 |
| Known as | Montanide ISA 51 VG | “Patients will be vaccinated 15 times over 12 months with a vaccine comprised of native and synthetic break-point cluster region-Abelson murine leukemia(BCR-ABL) specific...” NCT00428077 ↗25“NY-ESO-1 recombinant protein (250 µg) was mixed with Poly-ICLC (1 mg) and Montanide ISA-51 VG (1 mL) and administered SC directly following the ipilimumab infusion every 3...” NCT01810016 ↗ “Will receive an admixture of the wildtype and epitope enhanced TARP peptides emulsified with Montanide ISA 51 VG and granulocyte-macrophage colony-stimulating factor (GM-CSF).” NCT00972309 ↗ “FusionVAC-22 peptide will be administered subcutaneously (s.c.) with the TLR1/2 ligand XS15 (50 µg) emulsified in Montanide ISA 51 VG (1:1).” NCT06789198 ↗ “Peptides will be administered subcutaneously (s.c.) together with the TLR1/2 ligand XS15 emulsified in Montanide ISA 51 VG as adjuvant” NCT05014607 ↗ “P10s-PADRE vaccine combined with MONTANIDE™ ISA 51 VG "Chemotherapy" Subcutaneous injection” NCT02264236 ↗ “the Toll-like receptor 1/2 ligand XS15 (50 μg) emulsified in Montanide ISA 51 VG (1:1).” NCT05937295 ↗ “NY-ESO-1 recombinant protein mixed with CpG 7909 and Montanide ISA-51 VG” NCT00299728 ↗ “P16_37-63 peptide combined with Montanide® ISA-51 VG” NCT02526316 ↗ “P10s-PADRE/MONTANIDE ISA 51 VG vaccine” NCT03003195 ↗ “mixed with 0.3 ml Montanide ISA-51 VG” NCT01462838 ↗ |
| Known as | Montanide ISA-51 | “Arm 1, vaccine alone: patients received i.d. injections of Melan-A: 26-35 (A27L) and gp100: 209-217 (210M) peptides (250 µg each) formulated in Montanide ISA-51 plus s.c....” NCT00559026 ↗43“Participants were randomly assigned (1:1:1), using block randomisation and a computer-generated randomisation sequence, to treatment with either 200 nmol of AGS-v vaccine...” PMID 32534628 ↗ Jun 2020 “PD-L1 peptide (100 micrograms) emulsified with the adjuvant Montanide ISA-51 given subcutaneously 10 times every second week over the course of 26 weeks including a five-week break.” NCT03850522 ↗ “Montanide ISA™ 51 is a water-in-oil (W/O) emulsion composed of a mineral oil and a surfactant from the mannide monooleate family with immune stimulatory effect .” NCT06218511 ↗ “CDCA1，URLC10，KIF20A，DEPDC1 and MPHOSPH1 peptides (0.5, 1 or 2mg of each peptide) mixed with Montanide ISA 51 will be administered by subcutaneous injection.” NCT01259505 ↗ “PEP-CMV Component A mixed with Montanide ISA-51 (1:1 volume ratio) intradermally administered half in the RIGHT groin and half in the LEFT groin.” NCT03299309 ↗ “URLC10-117 peptide(1mg), VEGFR1 peptide(1mg) and VEGFR2 peptide(1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.” NCT00681421 ↗ “Subcutaneous injection in the upper arm with 500mcg of FLU-v as 0.5ml emulsion in 0.25ml of WFI and 0.25ml of adjuvant Montanide ISA-51” NCT03180801 ↗ “Patients receive carcinoembryonic antigen peptide 1-6D (CAP 1-6D) emulsified in Montanide ISA-51 adjuvant subcutaneously on day 1.” NCT00012246 ↗ “100 micrograms (mcg) granulocyte-macrophage colony-stimulating factor (GM-CSF) and 1 milliliter (mL) of Montanide ISA-51 adjuvant.” NCT05479045 ↗ “On each vaccination day, the URLC10 peptide (1mg) mixed with Montanide ISA 51 will be administered by endodermic injection” NCT00753844 ↗ |
| Known as | Montanide(R) ISA-51 | “a synthetic CpG 7909 ODN (deoxycytidyl-deoxyguanosin oligodeoxy-nucleotides) mixed with NY-ESO-1 peptide p157-165 and incomplete Freund's adjuvants (Montanide(R) ISA-51) led to...” PMID 19728336 ↗ Feb 2010 |
| Modality | Other / unclassified | “incomplete Freund's adjuvant” NCT00003339 ↗ |
| Route | Subcutaneous | “injected subcutaneously every four weeks” NCT00001703 ↗ |